{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-099389","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.251566+00:00","generated_at":"2026-05-17T23:52:52.486583+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Repligen Q2 revenue $182M (+17% organic non-COVID); orders >20% YoY; raises FY guidance","bullets":["Revenue $182M, up 15% reported and 17% organic non-COVID YoY.","GAAP EPS $0.26 vs $0.10; adjusted EPS $0.37 vs $0.40.","Orders grew >20% YoY and sequentially, 8th consecutive quarter of orders exceeding non-COVID revenue.","Raises FY2025 revenue guidance to $715-$735M, organic non-COVID growth 12.5%-15.5%.","All franchises grew YoY; consumables >20%, biopharma +20%, all geographies mid-teens."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-099389","json":"https://secwatch.observer/filing/0000950170-25-099389.json","markdown":"https://secwatch.observer/filing/0000950170-25-099389.md","text":"https://secwatch.observer/filing/0000950170-25-099389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000095017025099389/0000950170-25-099389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000095017025099389/rgen-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:52:52.486583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}